{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:24:44Z","timestamp":1776432284401,"version":"3.51.2"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/wnf.0b013e31816f2795","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T07:10:03Z","timestamp":1225350603000},"page":"69-74","source":"Crossref","is-referenced-by-count":32,"title":["The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia"],"prefix":"10.1097","volume":"32","author":[{"given":"Robert R.","family":"Conley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Patricia","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"1-3","key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","article-title":"Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review.","volume":"88","author":"Murphy","year":"2006","journal-title":"Schizophr Res"},{"issue":"2","key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr Bull"},{"issue":"4","key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","article-title":"Evaluation of treatment-resistant schizophrenia.","volume":"23","author":"Conley","year":"1997","journal-title":"Schizophr Bull"},{"issue":"2-3","key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2005.02.010","article-title":"A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.","volume":"76","author":"de Leon","year":"2005","journal-title":"Schizophr Res"},{"issue":"1-2","key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0169-328X(99)00030-3","article-title":"Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain.","volume":"66","author":"Hellstrom-Lindahl","year":"1999","journal-title":"Brain Res Mol Brain Res"},{"issue":"2","key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1096-8628(20000403)96:2<173::AID-AJMG10>3.0.CO;2-U","article-title":"Schizophrenia and smoking: evidence for a common neurobiological basis?","volume":"96","author":"Stassen","year":"2000","journal-title":"Am J Med Genet"},{"issue":"12","key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archpsyc.59.12.1085","article-title":"Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.","volume":"59","author":"Leonard","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol Psychiatry"},{"issue":"2","key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3940(00)01144-7","article-title":"Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome.","volume":"287","author":"Durany","year":"2000","journal-title":"Neurosci Lett"},{"issue":"4","key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0893-133X(00)00121-4","article-title":"Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.","volume":"23","author":"Breese","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0006-3223(97)00362-4","article-title":"Nicotinic receptor desensitization and sensory gating deficits in schizophrenia.","volume":"44","author":"Griffith","year":"1998","journal-title":"Biol Psychiatry"},{"issue":"12","key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1176\/ajp.150.12.1856","article-title":"Normalization of auditory physiology by cigarette smoking in schizophrenic patients.","volume":"150","author":"Adler","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"8","key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2005.09.004","article-title":"Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia.","volume":"59","author":"Tanabe","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"3","key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0165-1781(03)00022-2","article-title":"Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia.","volume":"117","author":"Olincy","year":"2003","journal-title":"Psychiatry Res"},{"issue":"6","key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0893-133X(02)00372-X","article-title":"Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study.","volume":"27","author":"Depatie","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(02)00324-X","article-title":"Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia.","volume":"27","author":"Smith","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.npp.1300881","article-title":"Effects of nicotine nasal spray on cognitive function in schizophrenia.","volume":"31","author":"Smith","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14622299050011151","article-title":"Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia.","volume":"1","author":"Dalack","year":"1999","journal-title":"Nicotine Tob Res"},{"issue":"4","key":"R19-3-20210203","first-page":"684","article-title":"Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia.","volume":"27","author":"Yang","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4088\/JCP.v66n0915","article-title":"Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia.","volume":"66","author":"Evins","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpsyc.63.8.907","article-title":"Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors.","volume":"63","author":"Brody","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-003-1750-1","article-title":"Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.","volume":"174","author":"Martin","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.npp.1301087","article-title":"Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.","volume":"32","author":"Schilstrom","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.","volume":"305","author":"Samochocki","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1124\/mol.64.5.1217","article-title":"The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release.","volume":"64","author":"Dajas-Bailador","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"7","key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1176\/appi.ajp.159.7.1244","article-title":"Galantamine for treatment-resistant schizophrenia.","volume":"159","author":"Allen","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"5","key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002826-200209000-00010","article-title":"Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.","volume":"25","author":"Rosse","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.4088\/JCP.v65n1219e","article-title":"Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.","volume":"65","author":"Arnold","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hup.751","article-title":"Galantamine may improve attention and speech in schizophrenia.","volume":"21","author":"Ochoa","year":"2006","journal-title":"Hum Psychopharmacol"},{"issue":"1-3","key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.schres.2006.03.039","article-title":"Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?","volume":"85","author":"Noren","year":"2006","journal-title":"Schizophr Res"},{"issue":"3","key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4088\/JCP.v68n0309","article-title":"Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.","volume":"68","author":"Caroff","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"R32-3-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e3280117feb","article-title":"A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.","volume":"22","author":"Lee","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"R33-3-20210203","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2006.04.006","article-title":"Galantamine improves cognition in schizophrenic patients stabilized on risperidone.","volume":"60","author":"Schubert","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"2","key":"R34-3-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.neuroimage.2005.08.013","article-title":"Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.","volume":"29","author":"Kumari","year":"2006","journal-title":"Neuroimage"},{"issue":"12","key":"R36-3-20210203","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1176\/ajp.156.12.1944","article-title":"Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, I: sensitivity, reliability, and validity.","volume":"156","author":"Gold","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R37-3-20210203","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.ajp.2007.07050724","article-title":"Galantamine for the treatment of cognitive impairments in people with schizophrenia.","volume":"165","author":"Buchanan","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R38-3-20210203","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"issue":"7","key":"R39-3-20210203","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia. Definition and reliability.","volume":"39","author":"Andreasen","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R40-3-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"10","key":"R42-3-20210203","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R43-3-20210203","first-page":"66","article-title":"Assessment of capacity to give consent to research participation: state-of-the-art and beyond.","volume":"1","author":"DeRenzo","year":"1998","journal-title":"J Health Care Law Policy"},{"issue":"2","key":"R44-3-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms.","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"issue":"4","key":"R45-3-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ajp.157.4.549","article-title":"Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates.","volume":"157","author":"Bilder","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R46-3-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2004.05.011","article-title":"Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects.","volume":"74","author":"Sumiyoshi","year":"2005","journal-title":"Schizophr Res"},{"issue":"2","key":"R47-3-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/schbul\/sbj013","article-title":"The structure of negative symptoms within schizophrenia: implications for assessment.","volume":"32","author":"Blanchard","year":"2006","journal-title":"Schizophr Bull"},{"issue":"8","key":"R48-3-20210203","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1176\/appi.ajp.2007.07020326","article-title":"Exacerbation of schizophrenia by varenicline.","volume":"164","author":"Freedman","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"8","key":"R49-3-20210203","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1176\/appi.ajp.2007.07010173","article-title":"Varenicline-induced manic episode in a patient with bipolar disorder.","volume":"164","author":"Kohen","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"3","key":"R50-3-20210203","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol Pharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200903000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:41:00Z","timestamp":1684615260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200903000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31816f2795","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}